Repositioning tolcapone as a potent inhibitor of transthyretin amyloidogenesis and associated cellular toxicity

Transthyretin (TTR) is a plasma homotetrameric protein implicated in fatal systemic amyloidoses. TTR tetramer dissociation precedes pathological TTR aggregation. Native state stabilizers are promising drugs to treat TTR amyloidoses. Here we repurpose tolcapone, an FDA-approved molecule for Parkinson's disease, as a potent TTR aggregation inhibitor. Tolcapone binds specifically to TTR in human plasma, stabilizes the native tetramer in vivo in mice and humans and inhibits TTR cytotoxicity. Crystal structures of tolcapone bound to wild-type TTR and to the V122I cardiomyopathy-associated variant show that it docks better into the TTR T4 pocket than tafamidis, so far the only drug on the market to treat TTR amyloidoses. These data indicate that tolcapone, already in clinical trials for familial amyloid polyneuropathy, is a strong candidate for therapeutic intervention in these diseases, including those affecting the central nervous system, for which no small-molecule therapy exists.

[1]  H. Goren,et al.  Familial oculoleptomeningeal amyloidosis. , 1980, Brain : a journal of neurology.

[2]  B. Ratcliff,et al.  Handbook of Parkinson's Disease , 1988, The Yale Journal of Biology and Medicine.

[3]  K. Sletten,et al.  Evidence that the amyloid fibril protein in senile systemic amyloidosis is derived from normal prealbumin. , 1988, Biochemical and biophysical research communications.

[4]  K. Sletten,et al.  Fibril in senile systemic amyloidosis is derived from normal transthyretin. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[5]  L. Braverman,et al.  Role of transthyretin in the transport of thyroxine from the blood to the choroid plexus, the cerebrospinal fluid, and the brain. , 1992, Endocrinology.

[6]  L. Bartalena,et al.  Thyroid hormone transport proteins. , 1993, Clinics in laboratory medicine.

[7]  Maria João,et al.  Transthyretin mutations in health and disease , 1995, Human mutation.

[8]  F. Tashiro,et al.  A 6-kb upstream region of the human transthyretin gene can direct developmental, tissue-specific, and quantitatively normal expression in transgenic mouse. , 1995, Journal of biochemistry.

[9]  G. Sedek,et al.  Optimizing levodopa pharmacokinetics with multiple tolcapone doses in the elderly , 1997, Clinical pharmacology and therapeutics.

[10]  C. Wurth,et al.  The most pathogenic transthyretin variant, L55P, forms amyloid fibrils under acidic conditions and protofilaments under physiological conditions. , 1999, Biochemistry.

[11]  Scott A. Peterson,et al.  Synthesis and evaluation of inhibitors of transthyretin amyloid formation based on the non-steroidal anti-inflammatory drug, flufenamic acid. , 1999, Bioorganic & medicinal chemistry.

[12]  P. Heizmann,et al.  Determination of the catechol-O-methyltransferase inhibitor tolcapone and three of its metabolites in animal and human plasma and urine by reversed-phase high-performance liquid chromatography with ultraviolet detection. , 1999, Journal of chromatography. B, Biomedical sciences and applications.

[13]  James C. Sacchettini,et al.  Rational design of potent human transthyretin amyloid disease inhibitors , 2000, Nature Structural Biology.

[14]  D. Henry,et al.  Consumption of NSAIDs and the development of congestive heart failure in elderly patients: an underrecognized public health problem. , 2000, Archives of internal medicine.

[15]  A. Olofsson,et al.  A comparative analysis of 23 structures of the amyloidogenic protein transthyretin. , 2000, Journal of molecular biology.

[16]  Rui M. M. Brito,et al.  Tetramer Dissociation and Monomer Partial Unfolding Precedes Protofibril Formation in Amyloidogenic Transthyretin Variants* , 2001, The Journal of Biological Chemistry.

[17]  J. Wallace,et al.  Pathogenesis of NSAID-induced gastroduodenal mucosal injury. , 2001, Best practice & research. Clinical gastroenterology.

[18]  J. Hamilton,et al.  Transthyretin: a review from a structural perspective , 2001, Cellular and Molecular Life Sciences CMLS.

[19]  J. Kelly,et al.  The V122I cardiomyopathy variant of transthyretin increases the velocity of rate-limiting tetramer dissociation, resulting in accelerated amyloidosis , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[20]  H. M. Petrassi,et al.  An engineered transthyretin monomer that is nonamyloidogenic, unless it is partially denatured. , 2001, Biochemistry.

[21]  J. Kelly,et al.  Synthesis, structure, and activity of diclofenac analogues as transthyretin amyloid fibril formation inhibitors. , 2002, Journal of medicinal chemistry.

[22]  C. Dobson,et al.  Inherent toxicity of aggregates implies a common mechanism for protein misfolding diseases , 2002, Nature.

[23]  J. Kelly,et al.  Sequence-dependent denaturation energetics: A major determinant in amyloid disease diversity , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[24]  T. Tokuda,et al.  Energetic Characteristics of the New Transthyretin Variant A25T May Explain Its Atypical Central Nervous System Pathology , 2003, Laboratory Investigation.

[25]  K. Lyons,et al.  Handbook of Parkinson's Disease, Fourth Edition , 2003 .

[26]  M. Saraiva,et al.  4 ′‐iodo‐4′‐Deoxydoxorubicin and tetracyclines disrupt transthyretin amyloid fibrils in vitro producing noncytotoxic species: screening for TTR fibril disrupters , 2003, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[27]  James C Sacchettini,et al.  Diflunisal analogues stabilize the native state of transthyretin. Potent inhibition of amyloidogenesis. , 2004, Journal of medicinal chemistry.

[28]  B. Ericzon,et al.  Ten years of international experience with liver transplantation for familial amyloidotic polyneuropathy: results from the familial amyloidotic polyneuropathy world transplant registry , 2004, Transplantation.

[29]  Joleen T White,et al.  Transthyretin aggregation under partially denaturing conditions is a downhill polymerization. , 2004, Biochemistry.

[30]  J. Kelly,et al.  Native state stabilization by NSAIDs inhibits transthyretin amyloidogenesis from the most common familial disease variants , 2004, Laboratory Investigation.

[31]  M. Saraiva,et al.  Selective binding to transthyretin and tetramer stabilization in serum from patients with familial amyloidotic polyneuropathy by an iodinated diflunisal derivative. , 2004, The Biochemical journal.

[32]  J. Kelly,et al.  Tissue damage in the amyloidoses: Transthyretin monomers and nonnative oligomers are the major cytotoxic species in tissue culture. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[33]  J. Kelly,et al.  The Biological and Chemical Basis for Tissue-Selective Amyloid Disease , 2005, Cell.

[34]  M. Saraiva,et al.  Kinetic assay for high-throughput screening of in vitro transthyretin amyloid fibrillogenesis inhibitors. , 2005, Journal of combinatorial chemistry.

[35]  Steven M. Johnson,et al.  Kinetic stabilization of an oligomeric protein by a single ligand binding event. , 2005, Journal of the American Chemical Society.

[36]  M. Hirano,et al.  Novel cell lines derived from adult human ventricular cardiomyocytes. , 2005, Journal of molecular and cellular cardiology.

[37]  Steven M. Johnson,et al.  Native state kinetic stabilization as a strategy to ameliorate protein misfolding diseases: a focus on the transthyretin amyloidoses. , 2005, Accounts of chemical research.

[38]  J. Kelly,et al.  Design, synthesis, and evaluation of oxazole transthyretin amyloidogenesis inhibitors. , 2005, Bioorganic & medicinal chemistry letters.

[39]  J. Kelly,et al.  Orally administered diflunisal stabilizes transthyretin against dissociation required for amyloidogenesis , 2006, Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis.

[40]  Yoshiki Sekijima,et al.  Diflunisal stabilizes familial amyloid polyneuropathy-associated transthyretin variant tetramers in serum against dissociation required for amyloidogenesis , 2006, Neuroscience Research.

[41]  C. Dobson,et al.  Protein misfolding, functional amyloid, and human disease. , 2006, Annual review of biochemistry.

[42]  D. Small,et al.  Transthyretin and familial amyloidotic polyneuropathy. Recent progress in understanding the molecular mechanism of neurodegeneration. , 2007, The FEBS journal.

[43]  M. Saraiva,et al.  Comparative in vitro and ex vivo activities of selected inhibitors of transthyretin aggregation: relevance in drug design. , 2007, The Biochemical journal.

[44]  E. Freire.  Do enthalpy and entropy distinguish first in class from best in class? , 2008, Drug discovery today.

[45]  Steven M. Johnson,et al.  Biochemical and structural evaluation of highly selective 2-arylbenzoxazole-based transthyretin amyloidogenesis inhibitors. , 2008, Journal of medicinal chemistry.

[46]  Steven M. Johnson,et al.  Toward optimization of the linker substructure common to transthyretin amyloidogenesis inhibitors using biochemical and structural studies. , 2008, Journal of medicinal chemistry.

[47]  A. Velázquez‐Campoy,et al.  Isothermal titration calorimetry: general formalism using binding polynomials. , 2009, Methods in enzymology.

[48]  W. Hines,et al.  Identification of metabolite profiles of the catechol-O-methyl transferase inhibitor tolcapone in rat urine using LC/MS-based metabonomics analysis. , 2009, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[49]  A. Velázquez‐Campoy,et al.  Chapter 5 Isothermal Titration Calorimetry , 2009 .

[50]  M. Saraiva,et al.  Binding of epigallocatechin‐3‐gallate to transthyretin modulates its amyloidogenicity , 2009, FEBS letters.

[51]  Charles C. Persinger,et al.  How to improve R&D productivity: the pharmaceutical industry's grand challenge , 2010, Nature Reviews Drug Discovery.

[52]  Anna Campain,et al.  Discriminating lymphomas and reactive lymphadenopathy in lymph node biopsies by gene expression profiling , 2011, BMC Medical Genomics.

[53]  F. Salvi,et al.  Transthyretin-related amyloidoses and the heart: a clinical overview , 2010, Nature Reviews Cardiology.

[54]  J. Kelly,et al.  Mechanisms of transthyretin cardiomyocyte toxicity inhibition by resveratrol analogs. , 2011, Biochemical and biophysical research communications.

[55]  J. Kelly,et al.  Dissecting the structure, thermodynamic stability, and aggregation properties of the A25T transthyretin (A25T-TTR) variant involved in leptomeningeal amyloidosis: identifying protein partners that co-aggregate during A25T-TTR fibrillogenesis in cerebrospinal fluid. , 2011, Biochemistry.

[56]  M. Saraiva,et al.  Natural polyphenols inhibit different steps of the process of transthyretin (TTR) amyloid fibril formation , 2011, FEBS letters.

[57]  R. Labaudinière,et al.  Tafamidis, a potent and selective transthyretin kinetic stabilizer that inhibits the amyloid cascade , 2012, Proceedings of the National Academy of Sciences.

[58]  Steven J. M. Jones,et al.  Drug repositioning for personalized medicine , 2012, Genome Medicine.

[59]  R. Labaudinière,et al.  Tafamidis for transthyretin familial amyloid polyneuropathy , 2012, Neurology.

[60]  Steven M. Johnson,et al.  The transthyretin amyloidoses: from delineating the molecular mechanism of aggregation linked to pathology to a regulatory-agency-approved drug. , 2012, Journal of molecular biology.

[61]  Acute hydrocephalus due to impaired CSF resorption in Toscana virus meningoencephalitis , 2013, Neurology.

[62]  E. Nordh,et al.  Repurposing diflunisal for familial amyloid polyneuropathy: a randomized clinical trial. , 2013, JAMA.

[63]  C. Lacroix,et al.  Effect on disability and safety of Tafamidis in late onset of Met30 transthyretin familial amyloid polyneuropathy , 2013, European journal of neurology.

[64]  I. Graef,et al.  AG10 inhibits amyloidogenesis and cellular toxicity of the familial amyloid cardiomyopathy-associated V122I transthyretin , 2013, Proceedings of the National Academy of Sciences.

[65]  J. Buxbaum,et al.  Age-related oxidative modifications of transthyretin modulate its amyloidogenicity. , 2013, Biochemistry.

[66]  Lei Z. Robinson,et al.  Quantification of Quaternary Structure Stability in Aggregation-Prone Proteins under Physiological Conditions: The Transthyretin Case , 2014, Biochemistry.

[67]  N. Reixach,et al.  Amyloidogenic and non-amyloidogenic transthyretin variants interact differently with human cardiomyocytes: insights into early events of non-fibrillar tissue damage , 2014, Bioscience reports.

[68]  O. Abián,et al.  A unified framework based on the binding polynomial for characterizing biological systems by isothermal titration calorimetry. , 2015, Methods.